Combination of lenvatinib, pembrolizumab and TACE significantly improved PFS in intermediate-stage HCC patients, but with higher severe side effects rate.
A phase 3 study, LEAP-012, found that the combination of lenvatinib and pembrolizumab with transarterial chemoembolization (TACE) significantly improved progression-free survival (PFS) for patients with intermediate-stage hepatocellular carcinoma (HCC). Median PFS was 14.6 months versus 10 months for TACE alone. While the combination showed efficacy, it also resulted in higher rates of severe side effects, affecting 71.3% of patients.
September 14, 2024
6 Articles